ArticleImmunology2019
Regulatory T cells in cancer: where are we now?
Article in Immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Regulatory T cells in cancer: from immunosuppression to therapeutic targeting.Frontiers in immunology · 2025Review
- Acquisition of suppressive function by conventional T cells limits antitumor immunity upon TScience immunology · 2023Article
- Identification of a novel cuproptosis-related gene signature for multiple myeloma diagnosis.Immunity, inflammation and disease · 2023Article
- The prognostic value of tumor mutational burden related 6-gene-based Risk Score in laryngeal cancer patients.BMC oral health · 2022Article
- EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment.International journal of molecular sciences · 2022Review
- Article
- A Darwinian perspective on tumor immune evasion.Biochimica et biophysica acta. Reviews on cancer · 2022Review
- Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Anti-PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Targeting Erbin in B cells for therapy of lung metastasis of colorectal cancer.Signal transduction and targeted therapy · 2021Article
- Clinical Significance ofPathology oncology research : POR · 2021Article
- Single-Cell Sequencing Reveals the Transcriptome and TCR Characteristics of pTregs andFrontiers in immunology · 2021Article
- Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3.Journal for immunotherapy of cancer · 2020Article
- Blocking inflammation to improve immunotherapy of advanced cancer.Immunology · 2020Review
- Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?Cancer drug resistance (Alhambra, Calif.) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
There have been substantial strides forward in our understanding of the contribution of regulatory T (Treg) cells to cancer immunosuppression. In this issue, we present a series of papers highlighting emerging themes on this topic relevant not only to our understanding of the fundamental biology of tumour immunosuppression but also to the design of new immunotherapeutic approaches. The substantially shared biology of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.